- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Enrollment closed: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (clinicaltrials.gov) - Jul 30, 2014 P3, N=1500, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Sep 2014 Enrolling by invitation --> Active, not recruiting
- |||||||||| Enrollment closed, Trial primary completion date: Accu-Chek Combo in Young Patients (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=15, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Dec 2014
- |||||||||| Trial completion, Enrollment change, Trial initiation date, Trial primary completion date, HEOR: HORA: Health Outcomes in Rheumatoid Arthritis in Greece (clinicaltrials.gov) - Jul 28, 2014
P=N/A, N=210, Completed, Trial primary completion date: Mar 2016 --> Nov 2012 Active, not recruiting --> Completed | N=460 --> 210 | Initiation date: Jan 2010 --> Jul 2010 | Trial primary completion date: Nov 2013 --> Jun 2012
- |||||||||| Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe
Enrollment closed, Trial primary completion date: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jul 28, 2014 P1, N=28, Active, not recruiting, Active, not recruiting --> Completed | N=460 --> 210 | Initiation date: Jan 2010 --> Jul 2010 | Trial primary completion date: Nov 2013 --> Jun 2012 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015
- |||||||||| pepinemab (VX15) / Vaccinex
Enrollment closed, Trial primary completion date: Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS (clinicaltrials.gov) - Jul 27, 2014 P1, N=50, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2015
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) - Jul 24, 2014 P4, N=600, Recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Dec 2014
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: Tocilizumab Treatment in Graves (clinicaltrials.gov) - Jul 23, 2014 P3, N=32, Recruiting, Trial primary completion date: Apr 2014 --> Dec 2014 Trial primary completion date: Dec 2013 --> Jun 2015
- |||||||||| Enrollment open, Trial initiation date, Trial primary completion date: SIAMMS-II: Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis (clinicaltrials.gov) - Jul 21, 2014
P1, N=6, Recruiting, Recruiting --> Completed | Trial primary completion date: May 2015 --> Jul 2014 Not yet recruiting --> Recruiting | Initiation date: Oct 2013 --> Jan 2014 | Trial primary completion date: Sep 2015 --> Sep 2016
- |||||||||| Trial completion, Enrollment change: A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 21, 2014
P1, N=15, Completed, N=94 --> 64 | Recruiting --> Terminated; Following the emergence of an unexpected pharmacodynamic effect, the sponsor has decided to conclude the study early without fully achieving its objective Recruiting --> Completed | N=40 --> 15
- |||||||||| Trial primary completion date: Evaluation of Coagulation in Multiple Sclerosis (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=100, Recruiting, Recruiting --> Completed | N=40 --> 15 Trial primary completion date: Jun 2013 --> Apr 2015
|